Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating featuresChad J. Creighton, Jenny C. Chang, Xiaoxian Li et al.|Proceedings of the National Academy of Sciences|2009Cited by 1.4k
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft ModelsXiaomei Zhang, Michael T. Lewis, Helen Wong et al.|Cancer Research|2013Cited by 485
HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 BlockadeAleix Prat, Mothaffar F. Rimawi, Tomás Pascual et al.|JNCI Journal of the National Cancer Institute|2019Cited by 168
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 TherapyMario Giuliano, Rachel Schiff, Huizhong Hu et al.|Clinical Cancer Research|2015Cited by 119
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancerMothaffar F. Rimawi, Rachel Schiff, Carmine De Angelis et al.|Breast Cancer Research and Treatment|2017Cited by 95